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ABSTRACT                        Glycation is a non-enzymatic reaction between the carbonyl groups of sugars and 
the amino groups of proteins, nucleic acids and lipids. This process results in the formation of 
early glycation products, which rearrange to form more stable advanced glycation end products 
(AGEs). Glycation has been linked to a number of diseases such as, Alzheimer’s, diabetes mellitus, 
cataract, Parkinson’s, physiological aging, etc. Synthetic sugar substitutes are known as artificial 
sweeteners. Like sugar, they contain reactive groups, which can interact with amino groups of 
macromolecules inducing damage by glycation. In the present study, non-enzymatic interaction 
between commercially available aspartame, saccharin and sucralose-based artificial sweeteners 
and amino acid lysine was performed in vitro. Also, plasma proteins like bovine serum albumin, 
human serum albumin, immunoglobulin G, blood clotting factors VIII and IX were incubated 
with aspartame and sucralose-based sweeteners. The results indicate that glycation reaction 
also occurs between proteins and these artificial sweeteners like sugars. This is the first report 
indicating involvement of artificial sweeteners in glycation.
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Introduction
The non-enzymatic interaction between lysine residues in 
proteins and sugars is generally known as Maillard reaction 
or the browning reaction (Maillard 1912). It is a deleterious 
biochemical process, in which the carbonyl group of sugars 
reacts with the amino group of proteins to form glycosylam-
ines, which on rearrangement form stable Amadori products 
(Monnier and Carami 1981). This early reversible stage is 
followed by the formation of more stable and irreversible 
advanced glycation end products (AGEs). Glycation products 
are synthesized continuously even at normal glucose levels, 
however, their deleterious effects are more pronounced 
when the glucose level in the blood increases above normal 
(Melpomeni et al. 2003). Glycation reactions are implicated 
in the development of diseases, such as Alzheimer’s disease, 
diabetes mellitus, atherosclerosis, dialysis related amyloido-
sis, as well as physiological aging (Thorpe and Bayens 1996). 
Among the amino groups, lysine is a preferred group for 
non-enzymatic sugar attachment and subsequent formation 
of AGEs (Arai et al. 1987). Glycation results in cross link-
ing and aggregation of proteins and this structural alteration 
disrupts the normal function of these glycated proteins (Lo 
et al. 1994). The complex process of glycation alters the bio-
logical activities of macromolecules like proteins and DNA, 
thus disrupting their metabolic processes and inhibiting their 
specific functions (Ali and Sharma 2015). Non-enzymatic 
glycation of bovine serum albumin (BSA) by glucose and 
fructose has been reported by Suarez and co-workers (1989). 
Similarly, an elevated blood glucose concentration in diabe-
tes is known to promote glycation of human serum albumin 
(HSA) (Anguizola et al. 2013). Glycation of immunoglobulin 
G (IgG) has been found to increase in diabetic patients and it 
is of major value as it affects the overall immune competence 
(Yadav et al. 2013). However, there are no reports on glyca-
tion of blood clotting factors VIII and IX. Synthetic sugar 
substitutes are known as artificial sweeteners. Some of the 
most commonly used commercially available artificial sweet-
eners, Equal (aspartame-based), Splenda (sucralose-based) 
and Sweetex (saccharin-based) have been used in the current 
study. In comparison to sugar, they provide very less calories 
and hence they attract normal and overweight customers alike. 
Also, diabetic people have difficulty in regulating their blood 
sugar levels, so they limit their sugar intake by using sugar 
substitutes. Animal studies have convincingly proven that arti-
ficial sugar substitutes cause increased food intake and weight 
gain. This is because the sweet taste of sweeteners triggers an 
insulin response, causing storage of blood sugar in tissues. 
However, artificial sweeteners do not lead to hypoglycaemia 
and sugar craving (Swithers 2008).
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Aspartame, a low calorie sweetener is about 200 times 
sweeter than sucrose. On consumption, aspartame is broken 
down into its components - aspartic acid, phenylalanine and 
a small amount of methanol (Stegnik 1987; Prodolliet and 
Bruelhart 1993). Carcinogenicity of aspartame has been re-
ported even at a daily dose of 20 mg/kg body weight, much 
less than the acceptable daily intake for humans (50 mg/kg 
body weight). Studies have shown that aspartame possesses 
antiinflammatory, antipyretic and analgesic action (La Buda et 
al. 2001; Sofferitti et al. 2006; Pradhan et al. 2011). In a study 
on patients with type 2 diabetes, it was shown that a sucrose 
meal and an aspartame-based meal induce a similar rise in 
glucose and insulin levels at baseline (Ferland et al. 2007). 
Hence, it would be damaging for diabetics to continue on 
consuming the sugarfree substitutes, considering they actually 
elevate blood glucose levels. Equal, a commercially available 
aspartame-based sweetener used in this study, contains 36 mg 
aspartame per 1 gram of sweetener with lactose and silicon 
dioxide as additives.
Sucralose is approximately 600 times sweeter than sugar 
and it is made by replacing three hydroxyl groups in sucrose 
with chlorine atoms. It is heat stable and it can therefore re-
place sugar in almost any food type. Sucralose belongs to a 
class of chemicals called organic chlorides, which is a cause 
of concern, as organic chlorides of some types are carcino-
genic or toxic (Tandel et al. 2011). Commercially available 
sucralose-based sweetener Splenda comprises of sucralose 
with maltodextrin and dextrose as fillers. Splenda is known to 
reduce the beneficial bacteria in the gut and alter the microbial 
composition (Abou-Donia et al. 2008). Early analysis asserted 
that ingested sucralose passes unchanged through the gastro 
intestinal tract, however subsequent studies suggested that a 
part of it is metabolized. Also, reports suggest that cooking 
with sucralose at high temperature results in the generation 
of toxic compounds called chloropropanols (Schiffman and 
Rother 2013). Ingestion of sucralose has been shown to cause 
an increase in plasma glucose and insulin concentrations 
(Pepino et al. 2013). Taken together, these findings indicate 
that sucralose is not a biologically inert compound.
Saccharin, the first artificial sweetener was originally 
synthesized in 1879. It is 300 to 500 times as sweet as sugar 
and is often used to sweeten dietary beverages, foods, tooth-
pastes, etc (Tandel et al. 2011). Investigations suggest that the 
consumption of saccharin containing products may result in 
obesity by interfering with fundamental physiological and ho-
meostatic processes (Hampton 2008). Most countries permit 
the consumption of saccharin at restricted levels, whereas, 
some other countries have imposed a ban on saccharin prod-
ucts. Sweetex contains sodium saccharin with silicon dioxide 
and stearic acid in undetermined amounts.
The current study is based on the fact, that like sugars, 
artificial sweeteners contain reactive groups, which can inter-
act with amino groups of macromolecules inducing damage 
by glycation. Moreover, some tabletop sweeteners contain 
additives like lactose and dextrose, which may enhance the 
damage due to glycation. Maillard reaction with commer-
cially available artificial sweeteners Splenda and Sweetex was 
performed for observation of browning, followed by the mea-
surement of Amadori products by periodate oxidation assay. 
The aspartame-based sweetener (Equal) was not considered 
for Maillard reaction as it involves boiling and aspartame is 
unstable at 100 °C. Splenda showed substantial browning in 
this preliminary assay, whereas the amount of browning in 
sample containing Sweetex was not considerable. In vitro 
glycation of the proteins bovine serum albumin (BSA), hu-
man serum albumin (HSA), immunoglobulin G (IgG) and 
blood clotting factors VIII and IX with Equal and Splenda 
was performed. The obtained results suggest that Equal and 




Bovine serum albumin, methylglyoxal and lysine were pro-
cured from Sigma Aldrich. Commercially available artificial 
sweeteners Equal, Splenda and Sweetex were used. All the 
other chemicals, which we used, were of high analytical 
grade.
Maillard reaction with artificial sweeteners
Lysine (0.1 g) was added to 10 ml of water and the pH was 
adjusted to 7.4. Test samples were prepared by adding either 
0.1 g of Sweetex or Splenda to tubes containing 10 ml lysine. 
Tubes containing 0.1 g Sweetex or Splenda each in 10 ml 
distilled water and another tube containing 10 ml lysine were 
used as negative controls, while a tube containing methylgly-
oxal and lysine was used as a positive control. The solutions 
were heated at 100 °C for 3 h in a boiling water bath and were 
observed for browning. Absorbance was measured at 420 nm 
using a spectrophotometer.
Periodate oxidation assay
Glycation (Amadori product) was measured by the periodate 
method of Ahmed et al. (1986) with minor modifications. 
Maillard reaction samples (0.5 ml) were incubated with 
0.1 ml of HCl (0.1 M) and 0.1 ml of NaIO
4
 (0.05 M) for 30 
min at room temperature. To terminate the oxidation, the 
samples were cooled on ice for 10 min and mixed with 0.1 
ml pre-cooled ZnSO
4
 (15%) in NaOH (0.7 M). The samples 
were vortexed throughout the addition and were centrifuged 
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for 10 min at 9000 g to remove precipitated zinc periodate. 
Supernatant (0.5 ml) was transferred to fresh test tubes. Form-
aldehyde detection reagent was freshly prepared by mixing 
46 μl of acetylacetone in 10 ml of 3.3 M ammonium acetate. 
A volume of 1 ml of prepared reagent was added to each tube 
and glycosylamines were allowed to develop by incubation at 
37 oC for 1 h. Absorbance was measured at 405 nm against a 
reagent blank using a spectrophotometer. 
In vitro glycation of proteins with Equal and 
Splenda
Plasma proteins (bovine serum albumin, human serum albu-
min, immunoglobulin G, blood clotting factors VIII and IX) at 
a concentration of 10 mg/ml were incubated with and without 
glucose, Splenda and Equal, at a final concentration of 90 mg/
ml for 7 days at 55 °C. All the incubations were carried out in 
0.1 M potassium phosphate buffer (pH 7.4) containing 3 mM 
sodium azide to prevent bacterial contamination. Browning 
was measured at 420 nm using a spectrophotometer.
Results
Maillard reaction with artificial sweeteners
An aqueous solution of lysine (pH adjusted to 7) and artificial 
sweeteners (Sweetex and Splenda) was heated at 100 °C for 
3 h. The solution with Splenda turned reddish brown, while 
the one with Sweetex turned yellow orange. The formation 
of Maillard product was measured at 420 nm. Figure 1 shows 
the amount of Maillard product formed in the lysine-artificial 
sweetener system, in comparison to the positive control 
containing methylglyoxal and lysine. It is apparent from 
the graph that Splenda produces more glycation product in 
comparison to methylglyoxal (120% approx.), whereas, the 
amount of glycation product produced by the Sweetex-lysine 
mixture is comparatively less.
Periodate oxidation assay
Periodate oxidation assay was performed to determine the 
amount of Amadori product produced in glycated samples. 
After the final incubation at 37  °C for 1 h, bright yellow 
colour was observed and absorbance was measured at 405 nm. 
Tubes containing Splenda/Sweetex and lysine were compared 
with positive control tubes containing methylglyoxal and 
lysine. As can be seen in the Figure 2, the amount of glyco-
sylamines in the glycated sample containing Splenda was 
found to be more than that in the glycated samples containing 
methylglyoxal and lysine (160%). However, sample contain-
ing Sweetex produced less glycosylamines as compared to 
methylglyoxal/lysine (80%).
Glycation of bovine serum albumin
Incubation of bovine serum albumin with glucose, Equal 
or Splenda at 55 °C for 7 days resulted in browning and the 
intensity of colour increased with incubation time (Fig. 3). 
Both Equal and Splenda caused more browning of bovine 
serum albumin than glucose.
Glycation of human serum albumin
When human serum albumin was incubated with glucose, 
Equal or Splenda at 55 °C for 7 days, it also resulted in brown-
ing like bovine serum albumin. However, the glucose/human 
Figure 1. Measurement of Maillard reaction with artificial sweeten-
ers.




serum albumin produced intense browning as compared to 
Equal and Splenda (Fig. 4). It was also observed that Splenda 
caused least browning as compared to glucose and Equal.
Glycation of immunogloblulin G
An incubation of immunogloblulin G with glucose, Equal or 
Splenda at 55 °C for 7 days resulted in browning. The maxi-
mum browning was observed in the tube containing Splenda 
and immunoglobulin G (Fig. 5). Equal also lead to browning 
of immunoglobulin G more than glucose. 
Glycation of blood clotting factor VIII
Both Equal and Splenda caused more intense browning 
(>120%) as compared to glucose when they were incubated 
with blood clotting factor VIII at 55 °C for 7 days (Fig. 6). 
However, the browning of factor VIII by Splenda was less as 
compared to immunoglobulin G.
Glycation of blood clotting factor IX
An incubation of blood clotting factor and sweeteners (Equal 
and Splenda) at 55 °C for 7 days caused less browning (ap-
prox. 80%) as compared to glucose (Fig. 7).
disscussion
The formation and accumulation of glycation products are 
major factors in the development of diabetic complications, 
atherosclerosis, Alzheimer’s disease and the aging process 
(Rahbar et al. 2003). Age-related diseases exhibit increased 
Figure 3. Glycation of bovine serum albumin (BSA) with glucose, Equal 
and Splenda. 
Figure 4. Glycation of human serum albumin (HSA) with glucose, 
Equal and Splenda.
Figure 5. Glycation of immunoglobulin G (IgG) with glucose, Equal 
and Splenda.




levels of glycation end products, supporting the idea that 
sugars and their metabolites can damage macromolecules, 
especially on their accumulation in cells and tissues (Suji 
and Sivakami 2004). Although the mechanism of this damage 
was first described almost a century back by Maillard (1912), 
however, the exact events are yet to be figured out. Nonethe-
less, the major mechanisms, by which advanced glycation 
end products cause damage to the biomolecules, include cross 
linking, aggregation and precipitation.
In the present study, the formation of Maillard product 
(browning) was detected by boiling a mixtue of Splenda and 
Sweetex with lysine and browning was observed only on 
co-incubation of lysine and the artificial sweetener. Intense 
browning was observed on glycation of lysine with Splenda, 
however with Sweetex the browning was less significant. 
The formation of Amadori product was then confirmed by 
performing the periodate oxidation assay as it detects the 
presence of glycosylamines. Samples glycated with Splenda, 
showed the presence of Amadori product in amounts com-
parable to glycation samples containing methylglyoxal and 
lysine. On the other hand, the sample containing Sweetex 
produced less amounts of glycosylamines as compared to 
methylglyoxal/lysine.
The results presented in this study indicate, that Equal 
and Splenda can glycate proteins like bovine serum albumin, 
human serum albumin, immunogloublin G, blood clotting 
factors VIII and IX in vitro. Also, Equal is more reactive than 
glucose in glycating proteins. In the case of human serum 
albumin and factor IX, although Equal was found to be less 
reactive in comparison to glucose, the browning observed is 
substantial. Additional studies can be essential to determine 
if similar effects are observed in vivo.
Conclusion
Sugar substitutes and artificially sweetened products are in 
great demand as they mimic the sweet taste of sugar sans 
the calories. Besides its benefits, studies have convincingly 
proven that artificial sweeteners cause weight gain, cancer and 
many other health hazards (Tandel 2011). It can be concluded 
from the evidence, presented in this study that Equal and 
Splenda can potentially cause glycation of proteins and the 
intensity of damage caused to macromolecules is comparable 
to that caused by sugars. In some cases, the amounts of glyca-
tion products have been observed to be substantially more in 
the presence of artificial sweeteners (Equal and Splenda) than 
in comparison to glucose or methylglyoxal. Hence, the use of 
these sweeteners as a replacement of sugar may provide less 
calories, it could be the cause of a host of glycation related 
diseases in addition to artificial sweetener related disorders.
Glycation products can damage the molecular structure 
of proteins and hence disrupt their function. The current 
study shows that Equal can bring about glycation of human 
serum albumin, immunoglobulin G and blood clotting factors 
VIII and IX. Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis of proteins glycated 
by methylglyoxal has shown structural alteration of proteins 
(Ali et al. 2014). Similar studies are required to study the ef-
fect of glycation on the structure of the proteins glycated by 
artificial sweeteners as disruption of their function may have 
serious consequences.
Numerous studies on artificial sweeteners present con-
clusions ranging from ‘safe only up to permissible levels of 
intake’ to ‘unsafe even if consumption is less than accept-
able daily intake’ (Tandel 2011). The scientific community 
is divided in their opinion on the safety aspect of artificial 
sweeteners. The findings in the current study suggest that 
it is necessary to investigate the health controversy over the 
perceived benefits of artificial sugar substitutes.
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